NEW YORK, NY--(Marketwired - Jul 30, 2015) - The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Xoma Corporation ("Xoma") (
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Northern District of California. If you purchased or otherwise acquired Xoma Corporation common stock between November 6, 2014 and July 21, 2015, inclusive, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements that Xoma Corporation's EYEGUARD-B clinical trial would succeed and/or surpass expectations across the study's primary endpoint. On July 22, 2015, defendants revealed that the Phase 3 EYEGUARD-B study had failed. On this news, the price of Xoma stock declined by $3.48 per share, or over 79%, on extremely heavy trading volume.
If you suffered a loss in Xoma Corporation you have until September 22, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.